Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality

Journal of Internal Medicine

Volumn 274, Issue 1, 2013, Pages 86-100

  Zimmermann, H W ^a,b   Reuken, P A ^c   Koch, A ^a   Bartneck, M ^a   Adams, D H ^b   Trautwein, C ^a   Stallmach, A ^c   Tacke, F ^a   Bruns, T ^b,c  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Ascites; Biomarker; Cirrhosis; Spontaneous bacterial peritonitis; Survival

Indexed keywords

BACTERIAL DNA; BIOLOGICAL MARKER; TOLL LIKE RECEPTOR; UROKINASE RECEPTOR;

ADULT; ARTICLE; ASCITES; ASCITES FLUID; BACTERIAL INFECTION; BACTERIAL PERITONITIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNITY; IN VITRO STUDY; INFLAMMATION; LIGATION; LIVER DYSFUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MORTALITY; NEUTROPHIL; OUTCOME ASSESSMENT; PARACENTESIS; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SERUM; SYNTHESIS;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ASCITIC FLUID; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI INFECTIONS; FEMALE; GERMANY; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; ODDS RATIO; PARACENTESIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84879116205     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12054     Document Type: Article

References (50)

1. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-31.
2. Arvaniti V, D'Amico G, Fede G et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-56.
3. Borzio M, Salerno F, Piantoni L et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001; 33: 41-8.
4. Malik R, Mookerjee RP, Jalan R. Infection and inflammation in liver failure: two sides of the same coin. J Hepatol 2009; 51: 426-9.
5. Reuken PA, Stallmach A, Bruns T. Mortality after urinary tract infections in patients with advanced cirrhosis - relevance of acute kidney injury and comorbidities. Liver Int 2013; 33: 220-30.
6. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
7. Cholongitas E, Betrosian A, Senzolo M et al. Prognostic models in cirrhotics admitted to intensive care units better predict outcome when assessed at 48 h after admission. J Gastroenterol Hepatol 2008; 23: 1223-7.
8. Thabut D, Massard J, Gangloff A et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007; 46: 1872-82.
9. Cazzaniga M, Dionigi E, Gobbo G et al. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol 2009; 51: 475-82.
10. Cervoni J-P, Thévenot T, Weil D et al. C-Reactive protein predicts short-term mortality in patients with cirrhosis. J Hepatol 2012; 56: 1299-304.
11. Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V et al. Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care 2012; 16: R149.
12. Koch A, Voigt S, Kruschinski C et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011; 15: R63.
13. Savva A, Raftogiannis M, Baziaka F et al. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. J Infect 2011; 63: 344-50.
14. Huttunen R, Syrjänen J, Vuento R et al. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011; 270: 32-40.
15. Mölkänen T, Ruotsalainen E, Thorball CW et al. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2011; 30: 1417-24.
16. Wittenhagen P, Kronborg G, Weis N et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 2004; 10: 409-15.
17. Uusitalo-Seppälä R, Huttunen R, Tarkka M et al. Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study. J Intern Med 2012; 272: 247-56.
18. Sidenius N, Sier CF, Ullum H et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000; 96: 4091-5.
19. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11: 23-36.
20. Eugen-Olsen J, Andersen O, Linneberg A et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010; 268: 296-308.
21. Backes Y, Van der Sluijs KF, Mackie DP et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 2012; 38: 1418-28.
22. Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009; 27: 157-72.
23. Zhou H, Wu X, Lu X et al. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B. Thromb Res 2009; 123: 537-42.
24. Zimmermann HW, Koch A, Seidler S et al. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int 2012; 32: 500-9.
25. Berres M-L, Schlosser B, Berg T et al. Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol 2012; 46: 334-8.
26. Haupt TH, Petersen J, Ellekilde G et al. Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study. Crit Care 2012; 16: R130.
27. Zimmermann HW, Seidler S, Nattermann J et al. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS ONE 2010; 5: e11049.
28. Zapater P, Francés R, González-Navajas JM et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology 2008; 48: 1924-31.
29. Bruns T, Sachse S, Straube E et al. Identification of bacterial DNA in neutrocytic and non-neutrocytic cirrhotic ascites by means of a multiplex polymerase chain reaction. Liver Int 2009; 29: 1206-14.
30. Bruns T, Peter J, Hagel S et al. The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection. Clin Exp Immunol 2011; 164: 346-56.
31. Todd RF III, Alvarez PA, Brott DA et al. Bacterial lipopolysaccharide, phorbol myristate acetate, and muramyl dipeptide stimulate the expression of a human monocyte surface antigen, Mo3e. J Immunol 1985; 135: 3869-77.
32. Juffermans NP, Dekkers PE, Verbon A et al. Concurrent upregulation of urokinase plasminogen activator receptor and CD11b during tuberculosis and experimental endotoxemia. Infect Immun 2001; 69: 5182-5.
33. Dekkers PE, Ten Hove T, Te Velde AA et al. Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia. Infect Immun 2000; 68: 2156-60.
34. Fujiwara T, Oda K, Yokota S et al. Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum. J Biol Chem 1988; 263: 18545-52.
35. Tzanakaki G, Paparoupa M, Kyprianou M et al. Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome. Eur J Clin Microbiol Infect Dis 2012; 31: 1157-62.
36. Backes Y, Van der Sluijs KF, Tuip de Boer AM et al. Soluble urokinase-type plasminogen activator receptor levels in patients with burn injuries and inhalation trauma requiring mechanical ventilation: an observational cohort study. Crit Care 2011; 15: R270.
37. Shetty S, Idell S. A urokinase receptor mRNA binding protein from rabbit lung fibroblasts and mesothelial cells. Am J Physiol 1998; 274: L871-82.
38. Yilmaz G, Köksal I, Karahan SC et al. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic inflammatory response syndrome. Clin Biochem 2011; 44: 1227-30.
39. Biggins SW, Kim WR, Terrault NA et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130: 1652-60.
40. Wasmuth HE, Kunz D, Yagmur E et al. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol 2005; 42: 195-201.
41. Xing T, Li L, Cao H et al. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure. Clin Exp Immunol 2007; 147: 184-8.
42. Reuken PA, Kiehntopf M, Stallmach A et al. Mid-regional pro-adrenomedullin (MR-proADM): an even better prognostic biomarker than C-reactive protein to predict short-term survival in patients with decompensated cirrhosis at risk of infection? J Hepatol 2012; 57: 1156-8.
43. Pliyev BK. Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87). Mol Cell Biochem 2009; 321: 111-22.
44. Pliyev BK, Menshikov MY. Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis. Inflammation 2010; 33: 1-9.
45. Pérez del Pulgar S, Pizcueta P, Engel P et al. Enhanced monocyte activation and hepatotoxicity in response to endotoxin in portal hypertension. J Hepatol 2000; 32: 25-31.
46. Márquez M, Fernández-Gutiérrez C, Montes-de-Oca M et al. Chronic antigenic stimuli as a possible explanation for the immunodepression caused by liver cirrhosis. Clin Exp Immunol 2009; 158: 219-29.
47. Emmanuilidis K, Weighardt H, Maier S et al. Critical role of Kupffer cell-derived IL-10 for host defense in septic peritonitis. J Immunol 2001; 167: 3919-27.
48. Albillos A, De la Hera A, González M et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-17.
49. Wei C, El Hindi S, Li J et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17: 952-60.
50. Renckens R, Roelofs JJTH, Florquin S et al. Urokinase-type plasminogen activator receptor plays a role in neutrophil migration during lipopolysaccharide-induced peritoneal inflammation but not during Escherichia coli-induced peritonitis. J Infect Dis 2006; 193: 522-30.